Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
Status:
Completed
Trial end date:
2007-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to ascertain if the extended schedule of Temozolomide, which
allows increased doses and potential depletion of the enzyme underlaying resistance, is a
more effective treatment of metastatic melanoma than single agent dacarbazine.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborator:
European Organisation for Research and Treatment of Cancer - EORTC